Stock Price Quote

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE428.60-3.2 (-0.74 %)
PREV CLOSE ( ) 431.80
OPEN PRICE ( ) 433.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21043
TODAY'S LOW / HIGH ( )425.95 435.80
52 WK LOW / HIGH ( )268.8 484.55
NSE429.25-2.25 (-0.52 %)
PREV CLOSE( ) 431.50
OPEN PRICE ( ) 432.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 95625
TODAY'S LOW / HIGH( ) 426.00 435.80
52 WK LOW / HIGH ( )268.9 485.1
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE, MCX

NEWS

31Aug Announcement under Regulation 30 (LOD
Appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors of th..
19Jul Jubilant Pharmova reports 87% fall in
Jubilant Pharmova has reported results for first quarter ended June 30,..
19Jul Jubilant Pharmova informs about presen
Pursuant to Provisions of Regulation 30 of Securities and Exchange Board..
29May Jubilant Pharmova informs about outcom
Pursuant to Provisions of Regulation 33 read with Regulation 30 and othe..
17Mar Jubilant Pharmova informs about commun
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit19498.8
Gross Profit 23 793.4
Operating Profit 2011411.1
Net Sales 21748101.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  3644.85 (2.20%)
M.Cap ( in Cr)4676.30
Astrazeneca Pharma I (BSE)
peergroup  4587.60 (1.71%)
M.Cap ( in Cr)11469.00
Bajaj Healthcare (BSE)
peergroup  464.90 (5.71%)
M.Cap ( in Cr)1283.05
NGL Fine-Chem (BSE)
peergroup  1994.80 (1.19%)
M.Cap ( in Cr)1232.39
Themis Medicare (BSE)
peergroup  1722.50 (1.28%)
M.Cap ( in Cr)1585.18

Shareholding Pattern

PROMOTERS 50.68%
NON-INSTITUTION 24.5%
MUTUAL FUNDS/UTI 0.41%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. was incorporated in the year 1978. Its today's share price is 428.6. Its current market capitalisation stands at Rs 6826.79 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8101.17 Cr and Total Income of Rs.9480.09 Cr. The company's management includes Naresh Kapoor, Shirish G Belapure, Arun Seth, Vivek Mehra, Sushil Kumar Roongta, Ashok Misra, Sudha Pillai, S Sridhar, R Kumar, Arvind Chokhany, Arjun Shanker Bhartia, Priyavrat Bhartia, Hari S Bhartia, Shyam S Bhartia.

It is listed on the BSE with a BSE Code of 530019 , NSE with an NSE Symbol of JUBLPHARMA and ISIN of INE700A01033. It's Registered office is at Bhartiagram ,Jyotiba Phoolay Nagar, Gajraula-244223, Uttar Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, KN Gutgutia & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.